Objectives: An outbreak of NDM-1-producing Citrobacter freundii and possible secondary in vivo spread of bla NDM-1 to other Enterobacteriaceae were investigated.
Introduction
New Delhi metallo-b-lactamase 1 (NDM-1), a metallo-b-lactamase (MBL), was first identified in 2008, in single isolates of Klebsiella pneumoniae and Escherichia coli from a Swedish patient, previously treated at a hospital in New Delhi, India. 1 The majority of Enterobacteriaceae with bla NDM-1 are often extensively co-resistant to multiple antimicrobial agents, but usually remain susceptible to colistin and tigecycline. 1, 2 The occurrence of NDM-producing Enterobacteriaceae is increasing worldwide. 3, 4 Several outbreaks of NDM-producing K. pneumoniae have been reported, while outbreaks of other species are still rare. 5 -8 Departments of clinical microbiology in Denmark submit suspected carbapenemase-producing Enterobacteriaceae (CPE) for verification and genotyping to the National Antimicrobial Resistance Reference Laboratory at Statens Serum Institut on a voluntary basis. During 2008 -13, 37 CPE were detected in Denmark. 9 Until the end of October 2012, all NDM-producing Enterobacteriaceae reported in Denmark were related to travel abroad. 10 -13 The spread of NDM-producing Enterobacteriaceae in hospitals has been investigated by several typing methods, including PFGE. For investigation of population structure and global bacterial epidemiology, MLST has been the gold standard. Furthermore, WGS has recently been applied to compare NDMproducing Enterobacteriaceae. 7 We report a long-term NDM-1-producing Citrobacter freundii outbreak and plasmid-borne secondary spread of an NDM-1 producing plasmid in vivo to other Enterobacteriaceae investigated by information obtained from WGS data.
Materials and methods

Setting and bacterial isolates
At the end of October 2012, a meropenem-resistant C. freundii was detected in a urine sample from a patient hospitalized in the haematology ward at Aalborg University Hospital. Located in the North Denmark Region (580 000 inhabitants), this 830 bed hospital serves all medical specialities. From October 2012 until February 2014, five additional clinical isolates of meropenem-resistant C. freundii were detected from the same patient, during his stay in the haematology ward and the infectious disease ward at Aalborg University Hospital (Figure 1 ). From April 2013 to February 2014, 17 meropenem-resistant Enterobacteriaceae isolates were obtained from clinical samples from three other patients in the haematology ward. Co-detection of meropenem-resistant C. freundii and K. pneumoniae, in the same sample from Patient 2 ( Figure 1 and Table 1 ), gave early reason to suspect in vivo spread of the resistance mechanism.
From March 2014 to April 2014, 14 meropenem-resistant Enterobacteriaceae isolates (5 C. freundii, 6 K. pneumoniae and 3 E. coli) were obtained from a fifth patient during his hospital stay in the infectious disease ward and ICU at Aalborg University Hospital. In November 2014, two meropenem-resistant C. freundii, two meropenem-resistant K. pneumoniae and one meropenem-resistant E. coli were detected from a sixth patient, staying at a minor regional hospital. The sixth patient had previously been hospitalized in the haematology ward, Aalborg University Hospital. In March 2015, three meropenemresistant isolates (one C. freundii, one E. coli and one Klebsiella oxytoca) were detected from a seventh patient.
In all seven cases, the first isolate of C. freundii harbouring NDM was detected in a clinical sample ( Table 1) . All of the cases were deemed clinically significant and all patients were treated with antibiotics, preferably colistin. It is likely that Patient 4 and Patient 6 died of the NDM-1-producing C. freundii infection, regardless of concurrent haematological disease. Patient 1 and Patient 2 died from their end-stage haematological illnesses. Both patients were colonized, but not infected, by the NDM-1-producing C. freundii at the time of death. Patient 5 died from complicated intraabdominal infection.
From October 2012 to March 2015, 45 isolates of meropenemresistant Enterobacteriaceae from seven patients were detected. Twenty-four of these, along with one meropenem-susceptible K. oxytoca, were referred to Statens Serum Institut for further susceptibility testing and WGS.
Infection control
Immediately upon detection of an isolate of meropenem-resistant C. freundii, patients were isolated in the ward and contact precautions were initiated. With the manifestation of the fourth case in the haematology ward in October 2013, an ongoing outbreak was suspected. A task force established by the Infection Control Division at Aalborg University Hospital decided to screen all patients in contact with the haematology ward. Hence, in a 14 day period starting 28 October 2013, all haematological patients, including patients admitted to and discharged from the ward, were subjected to anal screening for meropenem-resistant bacteria using eSwabs (Copan, Brescia, Italy). Swabs were plated directly onto ChromID CARBA (bioMé rieux, Marcy-l'É toile, France), then incubated for Table 1 . Origin, MLSTand resistance gene profiles of the 13 NDM-producing C. freundii, the 6 NDM-1-producing K. pneumoniae, the 4 NDM-1-producing E. coli, the NDM-1-producing K. oxytoca and the meropenem-susceptible K. oxytoca strA, strB, aac(6 ′ )-Ib-cr, aacA4, aadA1, aadA2, rmtC cmlA1 sul1, sul3 tet(A) dfrA12 cleaning and decontamination using the Glosair TM 400 system (Johnson & Johnson AB, Sollentuna, Sweden), were introduced during the screening period in both the haematology ward and associated ambulatory care facilities. In November 2014, the source of the outbreak was still unknown and the accumulating cases of meropenem-resistant C. freundii prompted the initiation of further infection control measures. Environmental screenings from the inside of all taps, shower heads and sink holes in the haematology ward were collected and processed similarly to the patient screenings described above.
Antimicrobial susceptibility
At Aalborg University Hospital susceptibility testing was performed using Neo-Sensitabs TM (Rosco Diagnostica, Taastrup, Denmark) according to EUCAST guidelines. Screening for reduced carbapenem susceptibility was done with ertapenem (10 mg), and the primary screening breakpoint applied for Enterobacteriaceae was an inhibition zone ,25 mm. All isolates with reduced ertapenem susceptibility were further screened by meropenem and imipenem Etest (bioMérieux) and KPC/MBL and OXA-48 Confirm Kit 98015 (Rosco Diagnostica) before being submitted to Statens Serum Institut.
At Statens Serum Institut, antimicrobial susceptibility testing was performed using Sensititre Trek panels (Thermo Scientific, Waltham, MA, USA) (aztreonam, cefotaxime, ceftazidime, cefepime, piperacillin/tazobactam, chloramphenicol, colistin, ertapenem, imipenem, meropenem, ciprofloxacin, gentamicin, tobramycin, sulfamethoxazole, tetracycline, tigecycline, trimethoprim) according to the manufacturer's instructions. The microbroth dilution method was executed in accordance with the CLSI. 14 Susceptibility to streptomycin, rifampicin, temocillin and fosfomycin was investigated using Etest (bioMé rieux). The reference strain E. coli ATCC 25922 was used for quality control.
Detection of bla NDM
The bla NDM gene was identified by PCR using primers NDM-F (5 ′ -GAAGCT GAGCACCGCATTAG-3 ′ ) and NDM-R (5 ′ -TGCGGGCCGTATGAGTGATT-3 ′ ) to amplify an internal fragment of 761 bp. From June 2014, the meropenemresistant isolates were tested for the presence of carbapenemase genes using the Xpert Carba-R on GeneXpert Infinity System (Cepheid, Sunnyvale, USA).
WGS and assembly
Genomic DNA was extracted from 24 NDM-producing isolates from the seven patients and a meropenem-susceptible K. oxytoca isolate from Patient 7 (DNeasy Blood and Tissue Kit, Qiagen, Copenhagen, Denmark). WGS data from the 25 isolates have been deposited at the National Center for Biotechnology Information (NCBI) (BioProject ID PRJEB12145).
Fragment libraries were constructed using the Nextera Kit (Illumina, Little Chesterford, UK) followed by 251 bp paired-end sequencing (MiSeq, Illumina) according to the manufacturer's instructions.
In addition to the 13 genomes of the Danish C. freundii isolates, the sequence data were aligned against the chromosome of the MTCC 1658 C. freundii reference genome (GenBank accession number ANAV00000000) using the Burrows-Wheeler Aligner (BWA). K. pneumoniae ATCC BAA-2146 (GenBank accession number CP006659) was used as the reference genome for comparison of the six K. pneumoniae isolates, K. oxytoca with GenBank accession number NC_016612 was used as the reference for comparison of the two K. oxytoca isolates and E. coli JJ1886 (GenBank accession number CP006784) was used as the reference for comparison of the four E. coli isolates. Identification of SNP variants was performed using the GATK Unified Genotyper with filtering using NASP (http://tgennorth.github.io/NASP/) to remove positions with less than×10 coverage and ,90% unambiguous variant calls, or within duplicated regions of the reference using NUCmer. 15 AMA 940 Phylogenetic analyses of the identified SNPs was performed using maximum parsimony implemented in MEGA 6.0.6. 16 The paired-end Illumina data were assembled using CLC Bio Genomic Workbench 8.0 (Qiagen, Aarhus, Denmark). Comparison of the sequences was also performed using CLC Bio Genomic Workbench 8.0.
Identification of resistance genes, plasmid replicon types and MLST
The ResFinder web server, version 2.1, PlasmidFinder (Enterobacteriaceae), version 1.2, and MLST web server, version 1.7 (www.genomicepidemiology. org), 9 -11 were used to identify acquired antimicrobial resistance genes, plasmid replicon types in silico and MLST profiles from the assembled WGS data, respectively. 17 For resistance genes, a threshold of 100% identity was used for the genes encoding b-lactamases and 98.00% identity for all other genes, and only full-length genes were included. ResFinder detects the presence of resistance genes, but not functional integrity and expression or resistance due to acquired variation in housekeeping genes.
Plasmid transmissibility
C. freundii AMA 332 was used as donor and the plasmid-free recipient was E. coli J53azideR (azide resistant). Conjugation was set up as follows. A sterile paper filter (pore diameter 0.2 mm, Advantech) was placed in the centre of a blood agar plate, 1 mL of donor culture and 1 mL of recipient culture in exponential phases of growth were mixed together and 500 mL of the mixture was placed on the paper filter, allowing the liquid to soak into the medium. After overnight incubation at 378C, filters were washed with 4 mL of 0.9% salt water and 100 mL of the suspension was inoculated onto BHI (Becton, Dickinson & Co., Difco TM ) agar plates with 1 mg/L meropenem and 100 mg/L sodium azide. After overnight incubation at 378C the presence of transconjugants was assessed.
Plasmid characterization
Plasmid DNA was extracted from a single transconjugant using the Qiagen Plasmid Midi Kit (catalogue number 12143) and subsequently subjected to Illumina MiSeq paired-end sequencing as described above. Furthermore, the plasmid was sequenced using the Pacific Biosciences platform (Pacific Biosciences, CA, USA). In short, purified plasmid DNA (spiked with chromosomal Sphingomonas spp. DNA as carrier) was fragmented using a g-TUBE (Covaris Ltd, Brighton, UK). Five micrograms of DNA in 150 mL was added to the g-TUBE and the tube was spun for 1 min at 4600 rpm, inverted and spun again. Then a size selection was performed on a BluePippin on a 0.75% gel cassette loaded with S1 ladder and a collection range from 10 to 50 kb. Libraries were built following the Pacific Biosciences 10 kb template protocol using the SMRTbell template prep kit 1.0 (Pacific Biosciences). Unligated fragments were removed by exonuclease treatment and the final library was purified twice using AMPure beads from Pacific Biosciences. Pacific Biosciences BindingCalculator (v2.3.1.1) was used to generate the loading protocol; the sample was loaded accordingly and sequenced on two cells with 360 min movies.
The pT1 plasmid was assembled using a hybrid assembly approach in SPAdes (version 3.7.0) where paired-end Illumina data were used for assembly and Pacific Biosciences reads were used to close gaps. This resulted in a 154437 bp contig that was confirmed to be circular by mapping Pacific Biosciences reads to the contig using BLASTN.
88.5% core genome coverage). Interestingly, a single SNP (A G) in position 44 571 of pT1 was detected in all isolates originating from Patient 5, but not in any of the other isolates of the study, supporting the (intra-patient) in vivo transfer hypothesis.
This hypothesis was further supported by comparison of a meropenem-resistant K. oxytoca and a meropenem-susceptible K. oxytoca, both isolated from Patient 7. The core genomes of the two isolates were highly similar (difference of 7 SNPs); however, the meropenem-susceptible isolate (AMA 946) differed from the meropenem-resistant isolate (AMA 942) only by these 7 SNPs and by the presence of the pT1 plasmid.
Our analysis supports the hypothesis of multiple transfers of an NDM-1-encoding plasmid in vivo. Similarly, Tijet et al. 18 recently reported in vivo transfer of an NDM-1-producing plasmid in a single patient. This has also been reported for KPC-3-producing plasmids 19, 20 Furthermore, the sequencing data from the NDM-1 plasmid (pT1) was compared by SNP analysis with the other completely sequenced IncA/C2 NDM-1-producing plasmids available at NCBI: plasmids pEC2-NDM-3 (KC999035), pNDM10469 (JN861072), pNDM10505 (JF503991), pNDM102337 (JF714412), pNDM-US (CP006661), pNDM-US-2 (KJ588779), pNDM-KN (NC_019153), pKP1-NDM-1 (NC_023908) and pNDM-PstGN576 (KJ802405). SNP analysis of the core plasmid genomes (covering 83% of the pT1 plasmid genome) suggests that all of these plasmids have highly conserved plasmid backbones (up to 7 SNP differences). Interestingly, an area upstream of bla NDM-1 in pT1 containing a complete type I restriction modification system was only found to be present in pT1 and pEC2-NDM-3, but not in the any of the other plasmids.
None of the seven patients had a history of recent travel. The long time span between cases (median of 4 months) indicated that a common external source was unlikely, and the epidemiological links in the haematology ward (Patients 1 -4, Patient 6 and Patient 7) and infectious disease ward (Patient 1 and Patient 5), paired with the data obtained from WGS, support the hypothesis that horizontal transmission between patients had taken place. Patient screenings were performed in order to identify possible routes of transmission and to identify patients in whom empirical treatment in case of neutropenic fever needed to be adjusted.
During the 14 day screening period in October -November 2013, 78 anal swab samples from 55 patients were collected. These patient screenings failed to reveal any additional cases. Only Patient 1 and Patient 4, already known to be colonized at the time of the screening, were positive. Patient 1 had been screened negative at admittance, but after 7 days of cefuroxime treatment for suspected pneumonia the patient was found positive in the sample taken at discharge, indicating prolonged gastrointestinal colonization. Since no new cases where identified, and since tracking of patients and beds was incomplete, no conclusions regarding transmission routes could be made and patient screenings were discontinued after the 14 day period.
Among the 33 environmental screening samples from 11 rooms and bathrooms, none yielded any growth of meropenem-resistant Enterobacteriaceae, meropenem-resistant Pseudomonas aeruginosa or meropenem-resistant Acinetobacter spp.
To date, the origin of the NDM-1-producing C. freundii remains unknown. During the preparation of this manuscript, six NDM-1producing C. freundii isolates were detected from six new patients (Patients 8-13), indicating that the outbreak has been ongoing for .3 years.
To our knowledge, clonal NDM-1 outbreaks with secondary horizontal spread have only been described for K. pneumoniae and E. coli in Canada, previously. 21 Outbreaks with carbapenemaseproducing C. freundii are rare. Previously, Gaibani et al. 22 reported a VIM-producing C. freundii outbreak in Italy, but, to our knowledge, our study is the first to disclose an outbreak of NDM-1-producing C. freundii.
